A new study published in the Cochrane Database of Systematic Reviews has revealed that psychedelic-assisted therapy may help reduce anxiety, depression, and existential distress in individuals facing life-threatening diseases.
MDMA (left), psilocybin (middle), and LSD (right).
Researchers from Brigham and Women’s Hospital (Boston), Dana-Farber Cancer Institute (Boston), University of Basel (Switzerland), Geneva University Hospitals (Switzerland), and the University of Freiburg (Germany) collaborated on the analysis, which focused on the potential therapeutic effects of substances like psilocybin, LSD, and MDMA.
The study, which was also published by the U.S. National Library of Medicine, reviewed six randomized controlled trials, involving 149 participants, with life-threatening illnesses such as cancer. The trials compared the effects of psychedelic-assisted therapy to placebo or active comparators, such as antidepressants. The therapy involved the use of classical psychedelics (psilocybin and LSD) and MDMA, paired with preparatory and integrative therapeutic sessions.
Continue reading